Actively Recruiting
Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers
Led by City of Hope Medical Center · Updated on 2025-11-21
500
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.
CONDITIONS
Official Title
Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed gastric adenocarcinoma.
- Underwent curative-intent resection (R0).
- Availability of pre- and postoperative plasma samples.
- Documented clinical follow-up data (recurrence/metastasis status).
- Provided written informed consent.
You will not qualify if you...
- Insufficient plasma volume or RNA quality for exosomal extraction.
- Presence of synchronous or metachronous malignancies.
- Received neoadjuvant chemotherapy without postoperative follow-up.
- Lack of consent or incomplete clinicopathologic data.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91016
Actively Recruiting
Research Team
A
Ajay Goel, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here